Brief: Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results, Highlights Recent Period Activity
14/11/2022 22:48
Nov 14 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS INC - NET LOSS FOR THREE MONTHS
ENDED
SEPTEMBER 30, 2022 WAS $4.49 MILLION, OR $0.18 PER SHARE
* INHIBIKASE THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES WERE $26.5 MILLION AS OF SEPTEMBER 30,
2022
Source text for Eikon: ID:nPn83HyVqa
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary